信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

未开盘 12-12 16:08:09

85.200

+1.550

+1.85%

最高85.950	最低83.000	成交量1,018万
今开84.500	昨收83.650	日振幅3.53%
总市值1,466亿	流通市值1,466亿	总股本17.21亿
成交额8.62亿	换手率0.59%	流通股本17.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":85.2,"timestamp":1765526889002,"preClose":83.65,"halted":0,"volume":10184978,"delay":0,"floatShares":1721000000,"shares":1721000000,"eps":-0.06415161363848669,"marketStatus":"未开盘","change":1.55,"latestTime":"12-12 16:08:09","open":84.5,"high":85.95,"low":83,"amount":862458025,"amplitude":0.035266,"askPrice":85.2,"askSize":19000,"bidPrice":85.1,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.7443467179822514,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":83.65,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0.4058449028512864,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.2085,"impliedVolPercentile":0.0122},"requestUrl":"/m/hq/s/01801/wiki","defaultTab":"wiki","newsList":[{"id":"2591265911","title":"信达生物参与中整协体重与形体管理分会成立，倡导科学减重与健康形体新理念","url":"https://stock-news.laohu8.com/highlight/detail?id=2591265911","media":"信达生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591265911?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:02","pubTimestamp":1765670565,"startTime":"0","endTime":"0","summary":"大会期间，中国整形美容协会体重与形体管理分会正式成立，标志着我国医美健康产业在该细分领域迈向系统化与规范化。中国整形美容协会体重与形体管理分会成立仪式引领科学信达生物担任常任理事单位，共促行业规范发展体重管理与形体健康正成为医学与美学结合的重要方向。12月6日，由中整协体重与形体管理分会发起，信达生物参与支持的骑行活动于海口江东大道海滨开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214080943a69f8589&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214080943a69f8589&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2097828557.USD","LU2097828805.USD","LU2097828474.EUR","LU2242644610.SGD","BK1589","LU2097828631.EUR","01801","BK1583","LU2097828714.EUR","HK0000165453.HKD","LU0455707207.USD","BK1161","LU0502904849.HKD","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591663791","title":"医药生物行业：生物安全法案出现积极变化 重视CXO机会！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663791","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663791?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"降息落地及政策不确定性消除，重视外需型CXO 投资机会：美联储12 月降息如期落地，26 年预期再降25 个基点。新版《生物安全法案》通过众议院投票，将递交参议院投票，政策不确定性即将消除。相比FY25 NDAA 中的《生物安全法案》，新版中的《生物安全法案》整体表述更温和，协商空间更大，我们认为新版《生物安全法案》对外需型CXO 公司的订单、业绩影响将相当有限，随着政策不确定性消除，板块估值压制有望得到解除。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214195634a44a07df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214195634a44a07df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0455707207.USD","HK0000165453.HKD","LU2097828805.USD","BK1583","BK1161","LU2328871848.SGD","LU2488822045.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828631.EUR","BK1589","LU2097828474.EUR","01801","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR"],"gpt_icon":0},{"id":"2591657917","title":"医药行业周报：IN VIVO CART：BD热门赛道 早期技术具备广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657917","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657917?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"核心观点：In Vivo CART赛道发展火热，2025年已经有四个MNC并购的案例发生。具体来看，In Vivo CART分为LNP和慢病毒两条技术路线，两条技术路线均具备显著特色。LNP路线来看，药物在临床前展现出了快速转染以及优异的靶向性特点，慢病毒路线中，Esobiotec等公司的BCMA In Vivo CART已经在小人群MM患者中展现非常好的早期数据。整体看，In VivoCART发展迅速，后续发展值得关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU2242644610.SGD","06821","LU0052750758.USD","06160","LU0708995583.HKD","BK1141","LU0320764599.SGD","02359","01801","LU2125910500.SGD","BK1583","BK1574","LU2045819591.USD","01177","BK1576","LU1046422090.SGD","BK1161"],"gpt_icon":0},{"id":"2591657861","title":"医药生物行业周报：2025国谈结果公布 关注相关公司投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657861","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657861?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"2025 国谈结果重磅公布，关注相关公司投资机会12 月7 日，国家医保局重磅发布2025 年医保谈判结果，此外还首次同步启动了商保目录的制定工作。2025 医保目录新增114 种药品，总体成功率达88%，谈判成功率创近7 年新高，最高降幅94%，新版目录自2026 年1 月1 日起正式执行。12 月第2 周医药生物下跌1.04%，医疗研发外包板块涨幅最大从月度数据来看，2025 年初至今沪深整体呈现上行趋势。本周医药生物下跌1.04%，跑输沪深300 指数0.96pct，在31 个子行业中排名第17 位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214143634a4495150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214143634a4495150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01801","03933","06160","06978","01167","BK1161"],"gpt_icon":0},{"id":"2591639919","title":"青少年肥胖减肥难？本土创新药临床试验12周减重超8公斤","url":"https://stock-news.laohu8.com/highlight/detail?id=2591639919","media":"金羊网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591639919?lang=zh_cn&edition=full","pubTime":"2025-12-13 14:53","pubTimestamp":1765608790,"startTime":"0","endTime":"0","summary":"玛仕度肽的临床数据青少年肥胖患者带来了解决方案。此次研究纳入了36名12-18岁的肥胖青少年，他们此前通过饮食运动干预12周后，BMI下降均不足5%，中位体重达95.83公斤，已属于中重度肥胖。12周后的结果显示，药物治疗组的减重效果显著。其中，4mg剂量组体重相对降低7.87%，平均减重7.72公斤；6mg剂量组效果更优，体重相对降低9.93%，平均减重8.65公斤，BMI分别较基线下降8.78%和10.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213145532a4466484&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213145532a4466484&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","BK1574","LU2097828714.EUR","BK1161","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","06978","BK1589","LU2097828805.USD","LU2488822045.USD","LU0455707207.USD","LU0502904849.HKD","LU2242644610.SGD","HK0000165453.HKD","01801","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2590570693","title":"智通港股空仓持单统计|12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570693?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:30","pubTimestamp":1765535405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月5日，未平仓空单比位列前三位为万科企业、中兴通讯、中远海控，空仓比分别为20.57%、17.63%、17.59%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01880","LU0315179316.USD","02382","IE00BZ08YR35.GBP","09863","01801","09995","LU0417516738.SGD","01530","02899","01276","06865","00522","LU1481107354.HKD","00763","82318","601318","LU0348767384.USD","SG9999004220.SGD","000002","00863","LU0821914370.USD","06613","SG9999002463.SGD","02202","09626","PAImain","01138","LU2097828631.EUR","LU1211504680.USD","06680","LU2476274720.SGD","LU0320764599.SGD","02228","00354","HPAD.SI","LU0235996351.USD","PNGAY","HK0000306685.HKD","01919","02498","01072","03145","02013","LU0370786039.SGD","LU2242644610.SGD","00839"],"gpt_icon":1},{"id":"2590725265","title":"巨头卷向“三重靶点”减重药，国内价格战即将打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2590725265","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590725265?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:36","pubTimestamp":1765532204,"startTime":"0","endTime":"0","summary":"巨头押注“三重靶点”减重药当地时间12月11日，礼来发布数据称，该公司在研的新一代GLP-1类减重药retatrutide在一项后期临床试验中帮助患者减重近29%。目前礼来的替尔泊肽不同剂量可帮助患者减重15%至21%。届时，礼来与竞争对手诺和诺德的竞争将延伸至口服减重药领域。与糖尿病药物相比，用于减重适应症的治疗药物的定价通常较高。而随着大量仿制药的上市，2026年，一场GLP-1药物的价格战也即将打响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212173720a69ba0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212173720a69ba0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0234572021.USD","01801","LU0456855351.SGD","LU1894683264.USD","NVO","LU0321505868.SGD","PFE","BK4160","IE00BLSP4452.SGD","SG9999001176.USD","SG9999002224.SGD","LU1093756325.SGD","SG9999013999.USD","BK4588","BK4568","LU1894683348.USD","LU1883839398.USD","IE0002270589.USD","IE00BBT3K403.USD","LU0225771236.USD","LU0321505439.SGD","BK4592","LU0289739699.SGD","BK4581","BK4599","LU1093756168.USD","SG9999011175.SGD","IE000M9KFDE8.USD","BK4534","LU0058720904.USD","SG9999002232.USD","SG9999001176.SGD","LU1057294990.SGD","03933","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4007","LU1066051498.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","BK4585","LU0306807586.USD","LU0122379950.USD","GIPR","SG9999003800.SGD","BK4532","BK4550","IE00BKVL7J92.USD","LU0170899867.USD","IE00B19Z3581.USD","SGXZ57979304.SGD","LU0154236417.USD"],"gpt_icon":1},{"id":"2590572609","title":"每日卖空追踪 | 信达生物 12月12日卖空量成交42.35万股，卖空比例为4.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590572609","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590572609?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528223,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月12日，涨1.85%，卖空量成交42.35万股，较上一交易日减少74.08%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216502195398b9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216502195398b9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","LU0502904849.HKD","LU0455707207.USD","LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","01801","BK1583","BK1589","HK0000165453.HKD","BK1161","LU2097828631.EUR","LU2097828474.EUR","LU2097828805.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2590571538","title":"信达生物12月12日主力净流入2459.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571538","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571538?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:15","pubTimestamp":1765527355,"startTime":"0","endTime":"0","summary":"12月12日, 信达生物股价涨1.85%，报收85.20元，成交金额8.6亿元，换手率0.59%，振幅3.53%，量比0.40。信达生物今日主力资金净流入2459.2万元，上一交易日主力净流出2497.6万元。该股近5个交易日下跌6.63%，主力资金累计净流出2.8亿元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3.8亿元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162716a69b758a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162716a69b758a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","LU2328871848.SGD","LU2097828474.EUR","LU0455707207.USD","HK0000165453.HKD","LU2097828805.USD","LU2097828714.EUR","BK1589","LU2242644610.SGD","BK1161","LU1969619763.USD","LU2488822045.USD","BK1583","LU0502904849.HKD","01801","LU2097828631.EUR"],"gpt_icon":0},{"id":"2590044578","title":"中国创新药企破局“青少年肥胖”难题信达生物发布最新研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2590044578","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590044578?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:38","pubTimestamp":1765521480,"startTime":"0","endTime":"0","summary":"12月12日，信达生物宣布其开发的GCG/GLP-1双受体激动剂玛仕度肽在中国青少年肥胖人群中的Ib期临床研究达主要终点。研究显示，经12周治疗，玛仕度肽可显著降低体重指数（BMI）和体重，并改善多项代谢指标。生活方式干预对肥胖青少年疗效有限，儿童肥胖单纯依靠生活方式教育逆转率低，开发适用药物和营造共同管理体重氛围是破解困局关键。本研究入组36例青少年肥胖参与者，按1:1:1比例随机分组接受不同剂量玛仕度肽或安慰剂治疗，结果显示玛仕度肽总体安全性和耐受性良好，除减重外，玛仕度肽组受试者多项指标均明显下降。基于该结果，信达生物计划启动注册临床III期研究，争取早日惠及青少年肥胖或超重群体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121214443795395373&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121214443795395373&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","HK0000165453.HKD","BK1589","LU0502904849.HKD","LU2097828805.USD","LU1969619763.USD","LU2097828557.USD","LU2328871848.SGD","LU2488822045.USD","BK1161","01801","LU2097828474.EUR","LU2097828631.EUR","LU0455707207.USD","06978","LU2242644610.SGD","LU2097828714.EUR","BK1583"],"gpt_icon":0},{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","159992","LU1951186391.HKD","LU0043850808.USD","LU2778985437.USD","HK0000165453.HKD","LU0181495838.USD","LU0516423091.SGD","LU0067412154.USD","LU2097828557.USD","LU0502904849.HKD","LU1226287529.USD","LU0359201612.USD","LU0634319403.HKD","LU1961090484.USD","01801","02142","LU0708995583.HKD","02616","LU0417516738.SGD","BK1161","01877","LU0359202008.SGD","09995","02269","LU1993786604.SGD","LU1969619763.USD","SG9999004220.SGD","01093","LU0540923850.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1588","LU1770034418.SGD","06160","LU0348766576.USD","01177","06185","LU2097828714.EUR","03329","09688","LU2097828631.EUR","LU0456827905.SGD","LU2242644610.SGD","09926","LU2328871848.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","06978","LU1242518931.SGD"],"gpt_icon":0},{"id":"1137408931","title":"信达生物在中国青少年肥胖患者的IIB期临床试验中显示出显著的减重和代谢益处","url":"https://stock-news.laohu8.com/highlight/detail?id=1137408931","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137408931?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:00","pubTimestamp":1765497611,"startTime":"0","endTime":"0","summary":"信达生物在中国青少年肥胖患者的IIB期临床试验中显示出显著的减重和代谢益处","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1969619763.USD","LU0502904849.HKD","BK1583","LU2097828805.USD","HK0000165453.HKD","LU2242644610.SGD","LU2097828714.EUR","BK1589","LU2097828557.USD","LU2488822045.USD","01801","LU0455707207.USD","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD"],"gpt_icon":0},{"id":"2590099512","title":"信达生物股价波动或与NRDL结果相关，评级增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2590099512","media":"摩根大通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590099512?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:13","pubTimestamp":1765444422,"startTime":"0","endTime":"0","summary":"这表明，尽管短期内股价可能受到NRDL结果的影响，但该行对信达生物的长期发展持乐观态度。同时，随着更多临床数据的披露，信达生物的产品竞争力将得到进一步验证，这或将对股价形成长期支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211173057979c8408&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211173057979c8408&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801"],"gpt_icon":0},{"id":"2590451206","title":"新突破不断，CAR-T疗法将迎来爆发期！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451206","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451206?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:09","pubTimestamp":1765444179,"startTime":"0","endTime":"0","summary":"总的来说，从国内外头部药企都在涌入CAR-T疗法赛道，并且创新成果不断来看，该赛道已成为一个技术持续革新、应用范围拓宽、商业模式逐渐清晰的庞大产业行业。未来，这些新突破，预计将推进行业迎来爆发期，实体瘤治疗将有望取得更大突破，广大患者也将迎来更多新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211171037a44212dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211171037a44212dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","01548","BK1583","HK0000165453.HKD","LU2097828631.EUR","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","BK1161","LU2097828805.USD","LU2097828474.EUR","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2590061512","title":"阿里健康：2026 财务年度中期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2590061512","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590061512?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:37","pubTimestamp":1765442269,"startTime":"0","endTime":"0","summary":"阿里健康截至2025年9月30日止六个月，总收入达167亿元人民币，同比增长17.0%。净利润额为12.7亿元人民币，同比大幅增长64.7%，净利润率由5.4%提升至7.6%。截至2025年9月30日，天猫健康平台在线商品数同比增长超24%至超过9700万个库存单位，服务商家数同比增长超39%至超过5.6万家。与本集团签约提供在线健康咨询服务的执业医师、执业药师和营养师合计增长12%超25万人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211183637979ca116&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211183637979ca116&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","BK1617","BK1142","BK1161","BK1615","BK1571","LU2328871848.SGD","BK1501","LU2097828474.EUR","BK1502","00241","LU2097828631.EUR","LU2097828714.EUR","BK1589","BK1584","BK1583","LU0455707207.USD","LU0502904849.HKD","BK1591","LU2097828805.USD","LU2097828557.USD","BK1515","BK1610","LU2488822045.USD","BK1189","HK0000165453.HKD","LU1969619763.USD","BK1247","01801"],"gpt_icon":0},{"id":"2590605175","title":"中国Biotech“反向授权”时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2590605175","media":"中国医药创新促...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590605175?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:36","pubTimestamp":1765424174,"startTime":"0","endTime":"0","summary":"日本武田制药与信达生物的合作涵盖了三种新型抗癌药物，包括双特异性抗体和ADC技术，这一数字刷新了中国生物科技公司对外授权的记录。这些数据汇集在一起，构成了中国创新药“反向授权”的壮丽图景。如科伦博泰同时与Windward Bio和Crescent Biopharma达成合作，总交易价值超过20亿美元。中国创新药企研发的首个靶向Claudin 18.2的ADC药物已经进入三期临床，这款药物的全球权益以数十亿美元的价格授权给国际药企，标志着一个新时代的开始。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211134144a7315326&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211134144a7315326&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","BK1589","LU2328871848.SGD","LU2097828714.EUR","01801","LU1969619763.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828557.USD","HK0000165453.HKD","LU2097828631.EUR","LU2488822045.USD","BK1161","LU0455707207.USD","LU0502904849.HKD","BK1583","03692"],"gpt_icon":0},{"id":"2590560665","title":"国产创新药多点突破，抢滩1000亿美元规模炎症性肠病药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560665","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560665?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:25","pubTimestamp":1765423552,"startTime":"0","endTime":"0","summary":"有数据预测，到2032年全球IBD市场将达到1000亿美元规模。如云顶新耀引进的S1P调节剂伊曲莫德已在国内申报上市。资料显示，伊曲莫德作为一种新一代高选择性S1P受体调节剂，通过与S1P受体1、4和5结合，发挥调节免疫和炎症的作用。此外，匹康奇拜单抗200 mg组和600mg组达到症状缓解、内镜缓解或黏膜愈合的受试者比例均高于安慰剂组。目前评估Hemay005用于中度至重度溃疡性结肠炎的有效性的一项临床II期研究正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211112914a7311dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211112914a7311dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1589","HK0000165453.HKD","LU2097828805.USD","LU1969619763.USD","LU2097828714.EUR","BK1583","LU2488822045.USD","LU2097828474.EUR","LU2328871848.SGD","BK1574","LU0455707207.USD","06978","LU2097828631.EUR","LU0502904849.HKD","LU2242644610.SGD","01801","LU2097828557.USD"],"gpt_icon":0},{"id":"2590568001","title":"创新药热潮与商业化红利共振 BD交易额破1200亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568001","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590568001?lang=zh_cn&edition=full","pubTime":"2025-12-11 08:42","pubTimestamp":1765413720,"startTime":"0","endTime":"0","summary":"跨国药企面临严峻的专利悬崖问题，中国创新药作为其管线补充的重要来源之一，在2025年迎来BD爆发元年，交易数据持续攀升。10月创新药BD交易仍然频繁，交易总额达200亿美元，截止10月底，2025年的BD累计交易总额已超过1200亿美元，同比增长190%，这表明BD交易已从偶发事件逐渐转变为行业常态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512110843099536967a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512110843099536967a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","06978","01877","BK1161","BK1574","BK1583","BK1515","01801"],"gpt_icon":0},{"id":"2590515763","title":"2026年医药行业策略报告：黄金赛道：寻找中国的GLOBALPHARMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515763","media":"西部证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590515763?lang=zh_cn&edition=full","pubTime":"2025-12-11 00:00","pubTimestamp":1765382400,"startTime":"0","endTime":"0","summary":"2025 年医药行业如期迎来了反转行情，以创新药为主导，CXO 及上游产业链受益，延伸到其他各个二级板块的涨幅均较为可观。创新药的核心催化来自于政策支持+BD 出海的行业逻辑不断兑现，三生制药、信达生物等首付款超10 亿美金的交易相继落地，验证了中国创新药的国际竞争力。BD 方面，2025 年中国药企license-out 数量呈现快速增长趋势。展望2026 年，我们认为创新药的行情将从“BD 为王”转变为“数据为王”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211134628a441a671&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211134628a441a671&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","LU0634319403.HKD","LU2488822045.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0540923850.HKD","BK1161","LU0348766576.USD","06978","LU0417516902.SGD","LU2476274308.USD","LU1720050803.USD","LU0348767384.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516738.SGD","LU0417516571.SGD","09926","LU0348783233.USD","LU0348784397.USD","BK1574","01801","LU0348827113.USD"],"gpt_icon":0},{"id":"2590746531","title":"每日卖空追踪 | 信达生物 12月10日卖空量成交168.7万股，卖空比例为16.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590746531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590746531?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355424,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月10日，跌1.07%，卖空量成交168.7万股，较上一交易日减少58.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163336979a468a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163336979a468a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","LU2488822045.USD","BK1589","LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","HK0000165453.HKD","LU0455707207.USD","LU2097828631.EUR","LU2097828805.USD","01801","LU2097828714.EUR","BK1583","LU1969619763.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0739},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.1293},{"period":"6month","weight":0.0558},{"period":"1year","weight":1.2362},{"period":"ytd","weight":1.3279}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.035915}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}